Background The risk of occurrence of adverse events can be the result of misuse of the drug. Minimising the risk can be defined as the set of actions that predict and reduce adverse events and actions to ensure the effectiveness of the measures taken.
Purpose The aim was to present the experience and actions of our National Institute of Oncology for minimising the risk of developing side effects.
Material and methods Establishment of an oral chemotherapy and hormone therapy dispensation unit under the supervision of a pharmacist and pharmacovigilance cell with a pharmacist in each clinical department.
Results During 2015, an oral chemotherapy dispensation unit was set up in the institute with a plan of action aimed at ensuring patient safety in terms of adverse effects. It touched on 4 actions: (1) actions during drug delivery; (2) actions relating to the interface between the pharmacist and the patient; (3) actions for written information about the drug; and (4) actions on the patient himself.
On the other hand, the pharmacovigilance cell contributed to surveillance for adverse events by pharmacists trained in this area; declaration of these effects, imputability analysis, development of action, avoidance and adverse event patient monitoring with telephone follow-up were among the cell’s mission.
Conclusion The pharmacist has an important role in consulting and in patient monitoring post chemotherapy, which prevents many adverse effects. However, extensive studies can optimise these interventions.
References and/or Acknowledgements
Monson R, et al. Role of the clinical pharmacist in improving drug therapy. Arch Intern Med 1981;141:1441-4
References and/or AcknowledgementsNo conflict of interest.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.